The Latest Breaking News from Barchart

South American weather, Russia-Ukraine peace deal, and China trade talks remain in focus for grains traders this week.

Argan moved up 40 spots yesterday, from 99th to 59th. Up 134% over the past 12 months, and its weighted alpha is considerably higher, momentum is most definitely on its side. The question is whether you’re too late to buy.

BigBear.ai shares rallied Monday as the management schedules a special shareholder meeting on Dec. 1. Here’s how you should play BBAI stock in the build-up to next week’s event.

Barchart’s top chart strategist explains why John Carter’s TTM Squeeze is a volatility indicator worth adding to your technical analysis tool kit.

Holiday demand and consumer confidence remain two key factors for traders to watch this week.

This company has a compelling case based on its chart, and I’m limiting my downside risk with options.

Bottom line: U.S. cattle supply is still critically tight; imports are a rounding error; the chart is broken; and the trend is down. Watch the Dec seasonal window and three correlated years, but demand confirmation before you swing. Survive first, profit second.

Palo Alto Networks' stock is well off its highs, despite producing stellar free cash flow and FCF margins for its fiscal Q1 ending Oct. 31. That implies its price target is at least 15% higher at $212 per share.

Palvella Therapeutics (PVLA) is a clinical-stage biopharma stock with no revenue or FDA pipeline. However, the stock has exceptional price momentum with shares up 508% over the past year. PVLA is trading at a new 2-year high and has strong technical indicators. Palvella is highly speculative. It is suitable for...

Earnings season is starting to die down a little, which may come as a relief for some after last week’s market carnage. This week, we only have a few key companies reporting including Alibaba, Zscaler, Deer & Company and Dell Technologies.

Chevron's Nov. 12 Investor Day outlined a cash flow plan that implies a potentially sizable dividend hike. It has averaged 7% over the 25 years, beating rivals. Even with a 5% hike in January, CVX stock looks undervalued.